Advertisement

Issue 13, Volume 128

Cover Figure: Cap structure of procoagulant platelets contributing to localized amplification of coagulation in thrombosis. See the article by Podoplelova et al.

WASHINGTON, September 29, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression
This plenary paper presents the first in-depth paired analysis that compares leukemic stem cell frequencies and their genomic instability in acute myelogenous leukemia (AML) at diagnosis and relapse. These data suggest a unique biological shift in phenotype that could explain the poor response to chemotherapy of relapsing AML.

The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies

T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
In a comprehensive and timely review, Hoyos and Borrello discuss mechanisms of immunosuppression and emerging immunotherapeutic modalities for multiple myeloma, including monoclonal antibodies, checkpoint inhibitors, vaccines, immune modulators, and cellular therapy. In a second paper, Ali et al provide the first clinical data that describe the safety and efficacy of adoptive therapy with patient-derived chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen in myeloma.

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells
Faitschuk and colleagues have developed a new chimeric antigen receptor (CAR)-bearing T-cell system for selective targeting Fc µ receptor–bearing chronic lymphocytic leukemia (CLL) cells with sparing of normal B cells. These CAR T cells against a novel target may have significant therapeutic potential for CLL.

Coagulation factors bound to procoagulant platelets concentrate in cap structures to promote clotting
This study reports the structural features of a small, specialized region of the surface of procoagulant platelets, generated in response to strong agonists (eg, thrombin) and termed the “cap.” It suggests that this cap structure facilitates localized amplification of coagulation in thrombosis.

The macrophage contribution to stress erythropoiesis: when less is enough
This paper addresses important questions about the extent of macrophage-dependent regulation of erythropoiesis in response to anemia. The results in two murine models significantly advance our knowledge about how erythroblast-macrophage interactions play roles in stress erythropoiesis.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
This comprehensive work presents a robust analysis of the clonal evolutionary patterns of myeloma in a cohort of uniformly treated patients with myeloma.

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.